Products & Services · Finite-lived intangible assets, period increase
Tukysa — Finite-lived intangible assets, period increase
Analysis
StatementSegment
CategoryCapital Allocation
SignalHigher is better
VolatilityModerate
First reportedQ1 2026
Last reportedQ1 2026
How to read this metric
An increase indicates active investment in the commercialization or technological development of the product, suggesting management's commitment to its long-term revenue potential.
Detailed definition
This metric represents the gross additions to finite-lived intangible assets, such as developed technology or patents, a...
Peer comparison
Similar to capitalized development costs or acquired product rights reported by peers in the oncology and specialty pharmaceutical sectors.
Metric ID:
pfe_segment_tukysa_finite_lived_intangible_assets_period_increaseHistorical Data
1 periods
| Q1 '26 | |
|---|---|
| Value | $580.00M |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Pfizer's tukysa — finite-lived intangible assets, period increase?
- Pfizer (PFE) reported tukysa — finite-lived intangible assets, period increase of $580.00M in Q1 2026.
- What does tukysa — finite-lived intangible assets, period increase mean?
- The total value of new finite-lived intangible assets added to the Tukysa product line during the period.